Xenetic Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Interim CEO and CFO James F. Parslow was granted 100,000 shares of restricted common stock in Xenetic Biosciences.
NASDAQ
Xenetic Biosciences Director Alexey Vinogradov was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.
NASDAQ
Xenetic Biosciences, Inc. Director Firdaus J. Dastoor was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.
NASDAQ
Xenetic Biosciences Director Roger D. Kornberg acquired 2,500 stock options with an exercise price of $2.17, vesting on December 31, 2026.
NASDAQ
Xenetic Biosciences Director Grigory G. Borisenko was granted 2,500 stock options with an exercise price of $2.17, vesting in one year.
NASDAQ
Director Roger D. Kornberg acquired 2,500 stock options in Xenetic Biosciences, Inc.
NASDAQ
Grigory G. Borisenko, a director at Xenetic Biosciences, Inc., acquired 2,500 stock options on December 11, 2024.
NASDAQ
A Xenetic Biosciences director, Firdaus J. Dastoor, acquired 2,500 stock options on December 11, 2024.
NASDAQ
A Xenetic Biosciences director, Alexey Andreevich Vinogradov, acquired 2,500 stock options on December 11, 2024.
NASDAQ
James Parslow, Interim CEO and CFO of Xenetic Biosciences, acquired 20,000 stock options on June 18, 2024.